期刊文献+

Target Delineation in High-grade Glioma Do CTV Margins Make a Difference? ESTRO ACROP versus RTOG Guidelines a Comparative Dosimetric Study

下载PDF
导出
摘要 Background and purpose:There exist two major consensus guidelines for target delineation in glioblastoma(GBM).Namely the established radiation therapy oncology group(RTOG)and the recently redefined European society for radiation oncology(EORTC)-advisory committee on radiation oncology practice(ACROP),clinical studies evaluating the pattern of recurrence with relation to the CTV margins have as of date not evidenced statistically significant difference in relation to the two guidelines.However,considering the standardization of concurrent chemo-radiation with Temozolomide nearly 20%off patients can be expected to survive 2years or beyond.Quality of life issues will play a higher role in defining the better protocol.In the current study,we have dosimetrically compared these guidelines in both perspectives.Material and methods:Thirty patients of GBM who had been planned for conformal radiotherapy during Jan 2017 to Feb 2019 were considered.Each patient dataset contoured with ESTRO-ACROP guidelines to create PLAN A and RTOG guidelines to create PLAN B.Both plans were compared to evaluate the volumetric difference in terms of PTV and the relative proximity to critical normal structures.Results:The median volume of brain irradiated to high doses(60Gy)was significantly greater in PLAN B,566cc vs 398 cc(P<0.0002).The organs at risk were better spared with PLAN A in terms of encroachment of high dose PTV volume.This achieved significance for Brainstem(P<0.01),Chiasma(P<0.04)and hippocampus(P<0.016).We were able to identify patients with PTV volume>400cc and with tumor in Parietal or Temporal regions wouldn’t benefit from PLAN A.Conclusion:The use of target delineation based on a single step plan,excluding expanded edema(ESTRO-ACROP)could potentially reduce high dose target volumes and significantly spare brainstem,optic-chiasma,and hippocampus.Patients with tumor volume<400 cc and frontal lesions are most likely to benefit.
出处 《Advances in Modern Oncology Research》 2018年第6期32-36,共5页 现代肿瘤学研究进展(英文)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部